Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin

Fig. 8

Schematic model depicting the promotion of esophageal squamous cell carcinoma (ESCC) cell metastasis. TOPK binds to γ-catenin and the deregulated γ-catenin activates the Src/GSK3β/STAT3 signaling pathway. TOPK also activates the ERK and Src/GSK3β/STAT3 signal pathway. These two activated pathways increase the cancer cell invasion and mobility and subsequently promote ESCC metastasis. Further, the TOPK inhibitor, HI-TOPK-032 inhibits the activated Src/GSK3β/STAT3 and ERK signaling pathways resulting in decreased ESCC metastasis

Back to article page